Treatment response in hemato‐oncology in the context of the German early benefit assessment of drugs compared to clinical practice-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment response in hemato‐oncology in the context of the German early benefit assessment of drugs compared to clinical practice

Published:2023-12 Issue:4 Volume:16 Page:451-454
ISSN:1756-5383
Container-title:Journal of Evidence-Based Medicine
language:en
Short-container-title:J Evidence Based Medicine

Author:

Baltes Nannette¹,Icks Andrea¹,Dintsios Charalabos‐Markos¹^ORCID

Affiliation:

1. Medical Faculty, Institute for Health Services Research and Health Economics Heinrich Heine University Düsseldorf North Rhine Westphalia Germany

Publisher

Wiley

Subject

Health Policy,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jebm.12575

Reference15 articles.

1. Reflections on the Changing Face of German Pharmaceutical Policy

2. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework

3. Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree

4. Overall Survival: Still the Gold Standard

5. Endpoints in cancer clinical trials

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP